A Randomized, Double-blind, Multi-center, Multi-national Trial to Evaluate the Efficacy, Safety, and Immunogenicity of SAIT101 Versus Rituximab as a First-line Immunotherapy Treatment in Patients With Low Tumor Burden Follicular Lymphoma
Phase of Trial: Phase III
Latest Information Update: 13 Mar 2018
At a glance
- Drugs Rituximab (Primary)
- Indications Follicular lymphoma
- Focus Therapeutic Use
- Acronyms RAMO-2
- Sponsors Archigen Biotech
- 08 Mar 2018 Planned End Date changed from 1 Nov 2018 to 1 May 2019.
- 08 Mar 2018 Planned primary completion date changed from 1 Jul 2018 to 1 Feb 2019.
- 09 Aug 2017 Planned primary completion date changed from 1 Jun 2018 to 1 Jul 2018.